An epitopic approach to designing and characterization of a multiple antigenic polypeptide against Botulinum neurotoxins A and E

World Journal of Microbiology and Biotechnology

Volumn 26, Issue 9, 2010, Pages 1659-1666

  Basiri, Mohsen ^a   Mousavi, Seyed Latif ^a   Basiri, Hossein ^b   Rasooli, Iraj ^a  

^a SHAHED UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Botulinum; Epitope; Neurotoxin; Recombinant vaccine

Indexed keywords

ANTIBODY TITERS; BALB/C MICE; BOTULINUM; BOTULINUM NEUROTOXINS; DILUTION LEVELS; E. COLI; ELISA ASSAY; INTERACTIVITY; LINEAR EPITOPES; SEROTYPES; SYNTHETIC GENES;

ESCHERICHIA COLI; VACCINES;

ANTIBODIES;

ESCHERICHIA COLI; MUS;

EID: 77955280735     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-010-0343-5     Document Type: Article

References (31)

1. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070.
2. Atassi MZ, Dolimbek BZ, Hayakari M, Middlebrook JL, Whitney B, Oshima M (1996) Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J Protein Chem 15: 691-700.
3. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76: 1314-1318.
4. Bandyopadhyay S, Clark AW, Dasgupta BR, Sathyamoorthy V (1987) Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem 262: 2660-2663.
5. Byrne MP, Smith LA (2000) Development of vaccines for prevention of botulism. Biochimie 82: 955-966.
6. Chen S, Kim JJ, Barbieri JT (2007) Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem 282: 9621-9627.
7. Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 44: 1029-1041.
8. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
9. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19: 5226-5237.
10. Dressler D, Adib SF (2005) Botulinum toxin: mechanisms of action. Eur Neurol 53: 3-9.
11. Dressler D, Saberi FA, Barbosa ER (2005) Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63: 180-185.
12. Hambleton P (1994) Botulinum toxin: structure and pharmacology. Eur Arch Otorhinolaryngol 251: 200-202.
13. Kitamura M, Iwamori M, Nagai Y (1980) Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta 628: 328-335.
14. Kubota T, Watanabe T, Yokosawa N, Tsuzuki K, Indoh T, Moriishi K, Sanda K, Maki Y, Inoue K, Fujii N (1997) Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl Environ Microbiol 63: 1214-1218.
15. Li L, Singh BR (1998) Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J Nat Toxins 7: 215-226.
16. Lim EC, Seet RC (2007) Botulinum toxin, Quo Vadis? Med Hypotheses 69: 718-723.
17. Maruta T, Dolimbek BZ, Aoki KR, Steward LE, Atassi MZ (2004) Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J 23: 539-552.
18. Maruta T, Dolimbek BZ, Aoki KR, Atassi MZ (2006) Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods 151: 90-96.
19. Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13: 1-8.
20. Mousavi ML, Montaser Kouhsari S, Nazarian S, Rasooli I, Amani J (2004) Cloning, expression and purification of Clostridium botulinum neurotoxin type E binding domain. Iran J Biotechnol 2: 183-188.
21. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, Kozaki S (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378: 253-257.
22. Ochanda JO, Syuto B, Ohishi I, Naiki M, Kubo S (1986) Binding of Clostridium botulinum neurotoxin to gangliosides. J Biochem 100: 27-33.
23. Oshima M, Middlebrook JL, Atassi MZ (1998) Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol Lett 60: 7-12.
24. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, Gong Y, Simpson LL (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75: 3043-3054.
25. Sharma S, Zhou Y, Singh BR (2006) Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A. Protein Expr Purif 45: 288-295.
26. Simpson LL (2007) Balancing the benefits and risks of a botulinum toxin vaccine. Expert Rev Vaccines 6: 883-886.
27. Smith LA (1998) Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36: 1539-1548.
28. Smith LA, Rusnak JM (2007) Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27: 303-318.
29. Sobel J (2005) Botulism. Clin Infect Dis 41: 1167-1173.
30. Walker JM (2002) The protein protocols handbook. Humana Press, Totowa.
31. Wu XC, Ye R, Duan Y, Wong SL (1998) Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. Appl Environ Microbiol 64: 824-829.